法瑞西单抗与阿柏西普治疗糖尿病黄斑水肿在20/50或更差视力亚组中的疗效:III期YOSEMITE和RHINE试验
该事后亚组分析基于YOSEMITE和RHINE两项III期随机双盲非劣效试验,评估基线最佳矫正视力(BCVA)为20/50或更差的糖尿病黄斑水肿(DME)患者接受法瑞西单抗6 mg与阿柏西普2 mg治疗2年的疗效。结果显示两种治疗在视力改善上相当,法瑞西单抗在视网膜厚度下降和注射次数上更具优势。
要点
- 在基线BCVA 20/50或更差的DME患者中,法瑞西单抗与阿柏西普的ETDRS BCVA平均变化相当。
- 法瑞西单抗Q8W和T&E组在第1年CST下降幅度大于阿柏西普Q8W组。
- 法瑞西单抗组首次CST<325 μm及首次视网膜内液消失的中位时间更短,平均注射次数更少。
核心结论
- 在基线ETDRS BCVA为20/50或更差的DME患者中,法瑞西单抗治疗与阿柏西普相比视力相当、视网膜厚度下降更大且注射次数更少。
研究设计与样本
- YOSEMITE和RHINE为设计相同的多中心、随机、双盲、阳性对照、非劣效性III期试验;事后亚组分析纳入基线BCVA 20/50或更差的意向治疗人群。
主要发现
- YOSEMITE中基线BCVA 20/50或更差者:法瑞西单抗Q8W组220例、法瑞西单抗T&E组220例、阿柏西普Q8W组219例;RHINE中分别为217例、219例、214例。
- 两项试验第1年和第2年ETDRS BCVA平均变化在各治疗组间相当。
- YOSEMITE第1年CST自基线校正平均变化:法瑞西单抗Q8W组-232.8 μm(P<0.0001)、法瑞西单抗T&E组-217.4 μm(P=0.0004),阿柏西普Q8W组-190.4 μm。
- RHINE第1年CST自基线校正平均变化:法瑞西单抗Q8W组-214.2 μm(P=0.0006)、法瑞西单抗T&E组-206.6 μm(P=0.0116),阿柏西普Q8W组-186.6 μm。
- 两项试验第2年CST自基线变化法瑞西单抗Q8W组大于阿柏西普组;法瑞西单抗组首次CST<325 μm和首次视网膜内液消失的中位时间更短,平均注射次数更少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diabetic Retinopathy Clinical Research Network Protocol T suggests that the response to treatment among patients with diabetic macular edema (DME) may vary depending on baseline best-corrected visual acuity (BCVA). We evaluated the efficacy of faricimab 6 mg versus aflibercept 2 mg over 2 years in patients with DME and baseline BCVA of 20/50 or worse enrolled in faricimab phase III trials. DESIGN: YOSEMITE and RHINE were identically designed, multicenter, randomized, double-masked, active comparator-controlled, noninferiority trials. PARTICIPANTS: Adults ≥18 years of age with center-involving macular edema secondary to type 1 or 2 diabetes. METHODS: Patients were randomized to faricimab every 8 weeks (Q8W), faricimab personalized treat-and-extend (T&E) regimen, or aflibercept Q8W. Post hoc subgroup analyses were conducted using the intention-to-treat population with baseline BCVA of 20/50 or worse. MAIN OUTCOME MEASURES: Changes in ETDRS BCVA and central subfield thickness (CST) from baseline to years 1 and 2 were compared between treatment arms using mixed-model repeated measures analyses. RESULTS: In YOSEMITE and RHINE, respectively, 220 and 217 patients in the faricimab Q8W arm, 220 and 219 patients in the faricimab T&E arm, and 219 and 214 patients in the aflibercept Q8W arm showed baseline BCVA of 20/50 or worse. In both trials, mean change in ETDRS BCVA was comparable between treatments across trials at years 1 and 2. In YOSEMITE, adjusted mean change from baseline in CST (μm) at year 1 was greater with faricimab Q8W (-232.8; P < 0.0001) and faricimab T&E (-217.4; P = 0.0004) ) versus aflibercept Q8W (-190.4). In RHINE, this was faricimab Q8W (-214.2; P = 0.0006) and faricimab T&E (-206.6; P = 0.0116) versus aflibercept Q8W (-186.6). In both trials, change from baseline in CST at year 2 was greater with faricimab Q8W versus aflibercept. The median time to first CST of <325 μm and first absence of intraretinal fluid was shorter in the faricimab arms versus the aflibercept arm, with fewer injections on average. CONCLUSIONS: In patients with DME and baseline ETDRS BCVA of 20/50 or worse, faricimab treatment resulted in comparable visual acuity, greater reduction in retinal thickness, and fewer injections compared with aflibercept. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Zarbin M, Tabano D, Ahmed A, et al. Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials. Ophthalmology. 2024. PMID: 38852921. doi:10.1016/j.ophtha.2024.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。